ClinicalTrials.gg
CompletedNCT07839637PJMOEUpdated Sep 24, 2026

Survey on Multiple Osteochondromas and Enchondromatoses During the Transition From Paediatric Care to Adult Care

An observational study in Multiple Osteochondroma and Enchondromatosis, sponsored by Istituto Ortopedico Rizzoli. Completed at 1 site in Italy. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Istituto Ortopedico Rizzoli · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
91
Ages
18 Years and older
Sex
All
01

Study summary

This prospective observational study aims to understand the transition experiences and unmet needs of patients living with multiple osteochondromas or enchondromatoses during the paediatric to adult care, in order to produce a Patient Journey by collecting data through an online survey.

Read the detailed description

The transition from paediatric to adult care represents a crucial phase for patients living with rare skeletal diseases, yet knowledge of patient experiences during this period remains limited. This study focuses on multiple osteochondromas and enchondromatoses, all rare bone conditions, providing guidance for patients, caregivers, and healthcare providers to improve care continuity and outcomes.

This study aims to recruit approximately 50 adult participants (≥18 years) across European countries. Participants will complete an online survey on their transition experience from preadolescence through adulthood. Results will be synthesized into a Patient Journey which will map the disease progression and the patient needs.

The research is conducted by the Department of Rare Skeletal Disorders at Istituto Ortopedico Rizzoli, Bologna, Italy, one of the reference centres, as well as the coordinating centre, of ERN BOND, the European Reference Network for rare BONe Diseases (https://ernbond.eu/), since its creation in 2017.

02

Conditions studied

  • Multiple Osteochondroma
  • Enchondromatosis
03

In context

Lead sponsor

Istituto Ortopedico Rizzoli is the lead sponsor of 304 studies on the registry; 103 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Individuals with enchondromatoses or multiple osteochondromas.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult subjects (≥ 18 years) affected by multiple osteochondromas or enchondromatoses.

Exclusion criteria

Exclusion Criteria:

  • Subjects not affected by multiple osteochondromas or enchondromatoses.
  • Minors
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
91 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Self reported experience of transition from paediatric to adult care

    Investigate via self-reporting tool used to evaluate the clinical symptoms experienced by adult patients subjective experiences of the transition phase in order to develop a Patient Journey that highlights clinical and psycosocial needs, care and gaps

    Time frame: Baseline, at the completion of the online questionnaire

07

Study locations

1 site
  • IRCCS Istituto Ortopedico Rizzoli
    Bologna, 40136, Italy
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2025 to primary completion in Jan 2026, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2025
First posted
Sep 24, 2026
StartActual
Nov 24, 2025
Primary completionActual
Jan 24, 2026
CompletionActual
Sep 18, 2026
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07839637
Responsible party
Luca Sangiorgi (Director of Department of Rare Skeletal Disorders, Istituto Ortopedico Rizzoli) — Principal investigator
First posted
Sep 24, 2026
Start date
Nov 24, 2025
Primary completion
Jan 24, 2026
Completion
Sep 18, 2026
Last update
Sep 24, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion